Enzymotec Ltd
ENZY
ENZY was delisted on the 10th of January, 2018.
0 hedge funds and large institutions have $0 invested in Enzymotec Ltd in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 37 closing their positions.
100% less funds holding
Funds holding: 37 → 0 (-37)
100% less capital invested
Capital invested by funds: $97.1M → $0 (-$97.1M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 37
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$24.9M |
| 2 |
DG
Delek Group
Herzliya,
Israel
|
-$23.7M |
| 3 |
Renaissance Technologies
New York
|
-$7.62M |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
-$6.83M |
| 5 |
GH
GAM Holding
Zurich,
Switzerland
|
-$6.28M |
ENZY Hedge Fund Activity: Q1 2018 in Review
0 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Enzymotec Ltd (ENZY) for Q1 2018, worth a combined $0 — down 100% from $97.1M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ENZY and 0 opened new positions — a net loss of 37 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Paulson & Co, exiting entirely with an estimated $24.9M sold.
- 0 institutional investors held Enzymotec Ltd (ENZY) as of Q1 2018, down from 37 in Q4 2017.
- Funds reported $0 of Enzymotec Ltd stock for Q1 2018, down 100% quarter-over-quarter.
- 0 funds opened new Enzymotec Ltd positions in Q1 2018 and 37 closed out, a net change of -37 holders.
- The largest Enzymotec Ltd seller in Q1 2018 was Paulson & Co, an estimated $24.9M sold.
Based on aggregated 13F filings for Q1 2018.